PDS Biotechnology Corp. (PDSB)

Over the past six months, PDSB's stock experienced several notable events. In November 2025, PDS Biotechnology reported its Q3 earnings with an EPS of -0.190 USD. In December 2025, the stock received an upgrade to "Buy" by Zacks. In February 2026, the company announced an amended protocol for its Phase 3 VERSATILE-003 trial, incorporating Progression-Free Survival (PFS) as a primary endpoint. In March 2026, PDS Biotechnology received a notice of Nasdaq Minimum Bid Price Deficiency, reported its full-year 2025 financial results showing a net loss of approximately $34.5 million, presented early Phase 2 data for PDS01ADC showing encouraging median PFS of 9.6 months and a 40% median PSA decline, and received new U.S. and Japan patents. In April 2026, the stock showed an upward trend, analysts reiterated "Buy" ratings, and the stock price was $1.07, representing an 11.08% increase over the past year.

PDS Biotechnology Corp. does not experience traditional demand seasonality for its products and services. The demand for its investigational drugs is driven by the progression of clinical trials, regulatory approvals, and the medical need for effective cancer treatments.

PDS Biotechnology Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for early and late-stage cancers, utilizing its Versamune® platform technology. Its lead product candidate, PDS0101, is being developed for HPV16-positive cancers, and PDS01ADC is in Phase 2 trials for advanced solid tumors.

PDS Biotechnology Corp. is headquartered in Princeton, New Jersey, United States. Its drug development activities are primarily in the U.S., with intellectual property protection for PDS0101 in the U.S., Japan, China, Australia, and Hong Kong. The company's stock is listed on NasdaqCM in the US and also on Deutsche Boerse AG (DB) in Germany.

PDS Biotechnology's brand reputation is influenced by its clinical development progress and intellectual property advancements. The FDA's alignment allowing PFS as a primary endpoint for the VERSATILE-003 trial, promising clinical data from the NCI-led trial investigating PDS01ADC, and the granting of new U.S. and Japan patents have positively impacted its reputation. A protocol-amendment update for the VERSATILE-003 trial drew a slight negative reaction, and ongoing net losses and high research and development expenses present a financial risk.

PDS Biotechnology Corporation's ownership is a mix of institutional, retail, and individual investors. Institutional investors hold between 5.96% and 12.99% of the stock, while insiders own between 1.54% and 2.58%. The general public and individual investors hold approximately 82.5% to 85.47% of the stock.